Oral News and Research

RSS

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Pfizer Inc. announced today that the Japanese Ministry of Health, Labor and Welfare has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies.

25 Mar 2013

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.

25 Mar 2013

Disinfectant mouthwashes may be effective against cancers of the mouth and throat

Patients who suffer from gingivitis are often advised to use disinfectant mouthwashes. In the future, the active ingredients in these products could be used in a completely different area: As scientists have reported in the journal Angewandte Chemie, Chlorhexidin and Alexidin increase programmed cell death and may be effective against cancers of the mouth and throat.

21 Mar 2013

HIV home tests: an interview with Dr Nitika Pant Pai, McGill University

30 years into the HIV epidemic, there is no vaccine in sight. Yet, even though there are fantastic and effective cheap and universally available drugs, and a treatment as prevention strategy is known to work, people do not wish to get tested for HIV! If everyone got tested, and treated, we could have brought the infection under control a long time ago!

21 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Experts provide guidebook for surgeons dealing with head and neck neoplasms

In this unique volume, leading international experts share their experiences in the management of head and neck tumors, providing a guidebook for all surgeons dealing with head and neck neoplasms.

21 Mar 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

Supreme Court considering generic drugmaker safety liability

The Supreme Court is weighing if generic drugmakers can be sued over the safety of their drugs or if federal regulators' safety approval is enough to block all such legal challenges.

21 Mar 2013

Biogen receives additional patent protection for MS drug TECFIDERA

Biogen Idec today announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,399,514, which offers additional protection for TECFIDERA (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis.

20 Mar 2013

European Congress on Osteoporosis & Osteoarthritis to start in April

Attend the European Congress on Osteoporosis & Osteoarthritis Rome, Italy from April 17-20, 2013 and earn up to 19 European Accreditation Council for Continuing Medical Education credits.

20 Mar 2013

Research provides better understanding of microbiological factors of periodontitis

Microbes from the human mouth are telling Oak Ridge National Laboratory scientists something about periodontitis and more after they cracked the genetic code of bacteria linked to the condition.

19 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

Salivary duct access products launched by Cook Medical to offer minimally invasive options for obstructive salivary gland disease

Cook Medical has launched a suite of salivary duct access products that offer minimally invasive options for the treatment of obstructive salivary gland disease. Minimally invasive treatment of obstructive salivary gland disease can reduce the need for invasive open surgery.

18 Mar 2013

Oral Cancer Foundation encourages dental practices to offer free oral cancer screenings in April

What has the greatest impact on survival rates of oral cancer? Radiation? Chemotherapy? Perhaps surgery? The truth is none of these; rather, it is the point in time at which the disease is discovered.

18 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

Deadline pressures could put more health exchanges in the federal government's hands

Reuters reports that if states that are pursuing their own insurance marketplaces can't keep up with the timeline, it could fall to Washington to run. Meanwhile, the Minnesota House approves legislation to set up its health exchange while advocates in Colorado press to make coverage of children's dental care mandatory in plans sold on that state's exchange.

16 Mar 2013

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

From Luminex 15 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.

14 Mar 2013

Brand-name and generic drug makers join forces to challenge FTC

Brand and generic drug companies are usually at each other' throats.

13 Mar 2013

Oral News and Research

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Disinfectant mouthwashes may be effective against cancers of the mouth and throat

HIV home tests: an interview with Dr Nitika Pant Pai, McGill University

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Experts provide guidebook for surgeons dealing with head and neck neoplasms

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

Supreme Court considering generic drugmaker safety liability

Biogen receives additional patent protection for MS drug TECFIDERA

European Congress on Osteoporosis & Osteoarthritis to start in April

Research provides better understanding of microbiological factors of periodontitis

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Salivary duct access products launched by Cook Medical to offer minimally invasive options for obstructive salivary gland disease

Oral Cancer Foundation encourages dental practices to offer free oral cancer screenings in April

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

Deadline pressures could put more health exchanges in the federal government's hands

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

Results from GTx's Phase 2 clinical trial of enobosarm published online

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Brand-name and generic drug makers join forces to challenge FTC

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News